Axios Pro Rata: Biotech bomb | Axios Pro Rata Summary

1. Key Themes

Theme: Geopolitics is reshaping biotech dealmaking, and the licensing carveout is the key variable

White House proposes wide-ranging limits on U.S.–China biotech deals

The proposed rules span deal structures and sectors, which matters for anyone with cross-border exposure.

"The White House yesterday proposed to restrict deals between U.S. and Chinese biotech companies, arguing that they could pose national security threats." "Deals subject to the new rules would include equity, debt, and joint ventures for almost all pharma compounds and their delivery systems, plus brain-computer interfaces, biomanufacturing equipment and other life sciences tools."

Licensing deals appear exempt, and both governments are carving them out

Licensing is the apparent arbitrage path, and China's own proposed restrictions mirror the exemption.

"One notable exception appears to be licensing deals, which have been on the rise." "China, which last week floated its own biopharma restrictions (also with the licensing carveout)."

The rule is not final and may be softened

The Dec. 7 comment deadline means near-term deal planning should consider a watered-down outcome.

"This can't go into effect until after the public comment period ends on Dec. 7, and there's at least some thought the final version could get watered down. Maybe Trump is coming in hot to gain leverage on China."

Theme: The IPO market is weaker than the headline numbers suggest

Record proceeds mask a thin market

Record IPO proceeds are driven by a single mega-issuer, while deal count is deeply depressed.

"Yes, proceeds already hit an all-time record — thanks largely to SpaceX, which generated over half of them. But the actual number of U.S. IPOs is down 34% from last year and almost surely will be the third-weakest year in the past decade."

Biotech is still getting IPOs done, and priced above plan

Lycia Therapeutics upsized and priced at the top of its range despite being a Phase 1 company, which signals a receptive window for well-backed biotech.

"It priced 17.6m shares at $18, versus plans to offer 14.7m at $16-$18. The Phase 1 company will list on Nasdaq (LYCA)."

Theme: Anthropic's IPO raises novel governance and index-inclusion questions

Index rule changes could force institutional ownership

Fast-entry index rules created for SpaceX mean large fiduciaries may have to own Anthropic regardless of their views.

"Given that Anthropic would get into indexes early, under new rules adopted for SpaceX, fiduciaries like Levine have basically no choice but to become a major shareholder."

The safety vs. growth tension under public ownership

Levine's concern is that public-market incentives could shift the company's priorities.

"Anthropic has argued that being public will enhance safety through forced transparency, but Levine worries that being public also could tip the company's internal north star from safety to growth."

Theme: Defense, space, and "frontier" tech continue to attract large rounds

Space infrastructure is pulling in large rounds

"Apex, an LA-based satellite maker, is in talks to raise around $500m at a $4b valuation." "Xona, a Burlingame, Calif.-based provider of commercial navigation infrastructure in low-Earth orbit, raised $250m in Series D funding at a $2.45b post-money valuation."

Defense-adjacent bets are getting seed-stage unicorn valuations

"Warhound, a developer of genetically engineered military dogs, raised $200 million in seed funding at a $1.2 billion post-money valuation."

Theme: Big Tech's AI capex is drawing investor skepticism

Meta's selloff is read as a warning on data center spending

"Investors are growing concerned that Big Tech's insistence on pouring more and more capital into data centers could end up costing them in the long run, as evidenced by Meta's stock drubbing yesterday."

2. Contrarian Perspectives

A top public pension fiduciary says "public, but not yet" for Anthropic

Rather than opposing AI companies going public, NYC Comptroller Mark Levine argues the timing is the problem: unresolved existential risk creates shareholder risk that passive index holders cannot avoid.

"Levine, who oversees more than $300 billion of public employee retirement funds, tells me that he believes companies like Anthropic should be public — just not yet." "His top concern is that Anthropic hasn't solved the existential threats it claims to pose, which would create massive shareholder risks."

"Record IPO year" is a misleading narrative

The consensus framing of a strong IPO year relies on one outlier; breadth tells the opposite story.

"Proceeds already hit an all-time record — thanks largely to SpaceX, which generated over half of them. But the actual number of U.S. IPOs is down 34% from last year."

The aggressive biotech restrictions may be a negotiating tactic

Primack floats that the sweeping proposal is leverage rather than a final policy position.

"Maybe Trump is coming in hot to gain leverage on China... there's at least some thought the final version could get watered down."

3. Companies Identified

Anthropic

Description: AI lab weighing a public offering.
Why mentioned: Facing public pushback from a major pension fiduciary over IPO timing.
Quote: "Anthropic... has less than a week to file if it wants to go public by Thanksgiving."

SpaceX

Description: Space company that has already gone public.
Why mentioned: Its IPO generated over half of 2026's record proceeds, and index rules adopted for it now affect Anthropic.
Quote: "Proceeds already hit an all-time record — thanks largely to SpaceX, which generated over half of them."

Warhound

Description: Developer of genetically engineered military dogs.
Why mentioned: $200M seed at $1.2B post-money from a long list of top-tier investors.
Quote: "The plan would be to breed dogs that are exceptionally equipped for tasks like bomb detection — which normie dogs already do."

Colossal Biosciences

Description: De-extinction company founded by Ben Lamm.
Why mentioned: Lamm's background is a credential for Warhound.
Quote: "Whose Colossal Biosciences 'de-extincts' species like dire wolves."

Anduril

Description: Defense technology company co-founded by Palmer Luckey.
Why mentioned: Luckey is a co-founder of Warhound.
Quote: "It's the brainchild of Ben Lamm... and Anduril's Palmer Luckey."

Andreessen Horowitz (a16z)

Description: Venture firm that rebranded its crypto unit.
Why mentioned: a16z Crypto became a16z Frontier amid a smaller fund and partner departure.
Quote: "Andreessen Horowitz has rebranded its a16z Crypto business to a16z Frontier, to focus on a broader batch of startups in markets that may take years to develop."

Megalith

Description: New co-investment firm.
Why mentioned: New firm launch focused on early-stage tech co-investments.
Quote: "Expect it to focus on co-investments in early-stage tech startups."

Apex

Description: LA-based satellite maker.
Why mentioned: In talks for ~$500M at a $4B valuation.
Quote: "Washington Harbour Partners would lead, joined by a16z and XYZ Venture Capital."

Xona

Description: Provider of commercial navigation infrastructure in low-Earth orbit.
Why mentioned: $250M Series D at a $2.45B post-money valuation.
Quote: "Raised $250m in Series D funding at a $2.45b post-money valuation led by Future Ventures."

Pathos AI

Description: NYC-based precision oncology startup.
Why mentioned: $237M Series E at a $3B post-money valuation, led by a strategic (Bristol Myers Squibb).
Quote: "Bristol Myers Squibb led, joined by insiders like NEA, Revolution, and Builders VC."

Warp Sciences

Description: Cambridge, Mass.-based chemistry CRO.
Why mentioned: $215M raise with a very broad generalist and tech investor syndicate.
Quote: "Lightspeed led, joined by Premji Invest, Mayfield, IVP, Lux, Conviction, Menlo Ventures..."

Star Therapeutics

Description: SF-based hematology and immunology biotech.
Why mentioned: $200M round led by specialist healthcare investors.
Quote: "OrbiMed and Janus Henderson led, joined by Agent Capital, Catalio Capital Management, Cormorant Asset Management..."

Tractian

Description: Atlanta-based AI platform for asset-heavy industries.
Why mentioned: $130M Series D at $1.4B valuation.
Quote: "Sapphire Ventures and M&G's Catalyst led, joined by N47, General Catalyst, Bosch Ventures..."

Formic

Description: Physical AI commercialization platform.
Why mentioned: $40M Series B plus $10M asset-backed financing.
Quote: "It also secured $10m in asset-backed financing from S2G Investments."

Mave

Description: Israeli agentic security operations platform.
Why mentioned: $28M Series A in AI-driven security.
Quote: "Red Dot Capital Partners led, joined by Lumir Growth Partners."

Lycia Therapeutics

Description: SF-based biotech targeting extracellular proteins; Nasdaq: LYCA.
Why mentioned: Raised $317.5M in IPO, upsized and priced at the top of range.
Quote: "It priced 17.6m shares at $18, versus plans to offer 14.7m at $16-$18."

Gilead Sciences

Description: Public biopharma.
Why mentioned: Large cash acquisition of an oral inflammation drug program.
Quote: "Agreed to acquire the oral inflammation drug program of PepStar Therapeutics for $1.275b in cash upfront."

Stonepeak

Description: Infrastructure investor.
Why mentioned: Acquired Chicago's parking meter operator from three institutional sellers.
Quote: "Stonepeak acquired Chicago Parking Meters... from Morgan Stanley Infrastructure Partners, Allianz, and Abu Dhabi Investment Authority."

Meta

Description: Big Tech company.
Why mentioned: Stock selloff tied to data center spending concerns.
Quote: "Meta's stock drubbing yesterday."

Pearl (David's Bridal)

Description: AI-based wedding planner.
Why mentioned: Planned spin-off and IPO at $350M valuation.
Quote: "Plans to spin off and take public Pearl, its AI-based wedding planner, at a $350m valuation."

Infineum

Description: Chemicals JV of Shell and ExxonMobil.
Why mentioned: Potential ~$8B sale.
Quote: "Hired BofA to sell Infineum, a chemicals JV that could fetch around $8b, per the FT."

Hadrian

Description: Manufacturer enabling domestic production.
Why mentioned: Featured in a sponsor message about venture debt.
Quote: "Hadrian is empowering manufacturers to produce domestically at greater speed and scale."

4. People Identified

Mark Levine

Description: NYC Comptroller overseeing more than $300B of public employee retirement funds.
Why mentioned: Publicly asked Anthropic to delay its IPO.
Quote: "His top concern is that Anthropic hasn't solved the existential threats it claims to pose, which would create massive shareholder risks."

Ben Lamm

Description: Founder of Colossal Biosciences.
Why mentioned: Co-originator of Warhound.
Quote: "It's the brainchild of Ben Lamm, whose Colossal Biosciences 'de-extincts' species like dire wolves."

Palmer Luckey

Description: Anduril co-founder.
Why mentioned: Co-originator of Warhound; has spoken publicly about "super soldiers."
Quote: "Palmer Luckey has talked publicly about creating 'super soldiers,' albeit via tech advancement rather than genetic engineering."

Michael Romero

Description: Co-founder of Megalith; 13 years in IR and ops at Lightspeed.
Why mentioned: Launching a new co-investment firm.
Quote: "Megalith has been launched by Michael Romero, who spent the past 13 years in IR and ops for Lightspeed Venture Partners."

Preston Moore

Description: Former Coatue investor; Megalith co-founder.
Why mentioned: Co-founding Megalith.
Quote: "...and former Coatue investor Preston Moore."

Ali Yahya

Description: a16z general partner since 2017.
Why mentioned: Leaving to start a new company.
Quote: "Ali Yahya, a general partner with the group, is leaving to launch a new company. He'd been with a16z since 2017."

Stephanie Zhan

Description: Sequoia Capital partner.
Why mentioned: Launching her own early-stage AI fund.
Quote: "Stephanie Zhan, a partner with Sequoia Capital, is launching her own early-stage AI fund."

Matthew Kaness

Description: Former CEO of ModCloth and GoodwillFinds.
Why mentioned: Joined Canaan Partners as an advisor.
Quote: "Matthew Kaness, former CEO of ModCloth and GoodwillFinds, joined venture firm Canaan Partners as an advisor."

5. Operating Insights

Structure cross-border biotech deals as licensing

If the proposed rules hold, licensing looks like the least-restricted structure, and it is already growing.

"One notable exception appears to be licensing deals, which have been on the rise."

Build in contingency for a regulatory window that is still open

Anyone with U.S.–China equity, debt, or JV plans has until the comment period closes to engage, and should avoid assuming the current draft is final.

"This can't go into effect until after the public comment period ends on Dec. 7."

Anticipate governance scrutiny from institutional investors before an IPO

Large asset owners are now willing to publicly challenge IPO timing, particularly where index inclusion makes ownership effectively mandatory.

"Fiduciaries like Levine have basically no choice but to become a major shareholder."

6. Overlooked Insights

a16z's fifth fund is less than half the size of its prior one, and may have shrunk further

Beyond the rebrand, the fund-size trend and LP friction are signals about how crypto-adjacent venture fundraising is performing.

"Fund V might no longer be exactly $2.2 billion, although I've been unable to learn the new number." "The group raised $2.2 billion for its fifth fund — less than half of what it raised for Fund IV in 2022."

Nonprofits are starting to acquire tech startups

The Harlem Children's Zone's purchase of a fintech startup is a small but unusual exit path for mission-aligned companies.

"Harlem Children's Zone acquired Goalsetter, a financial literacy tech startup that had raised over $25m... It is the nonprofit's first acquisition of a tech startup."